Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer

University Hospital, Rouen6 enrolled

Overview

Patients treated on the first line of Sunitinib-targeted therapy for metastatic kidney cancer. Collection of additional blood tubes during routine blood tests for patient follow-up, to evaluate the plasma concentration of Sunitinib and its active metabolite desethyl-Sunitinib (DES)

Study Type

OBSERVATIONAL

Enrollment

Conditions

Metastatic Kidney Cancer

Interventions

blood sampleBIOLOGICAL

blood sample performed on C1D1, C1D14, C2D1, C3D1 and C6D1

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient at least 18 years old * Patient who read and understood the newsletter and signed the consent form * Renal cell carcinoma histologically proven stage IV * Metastatic stage proven on CT, synchronous or metachronous examination * Patient operated on or not from the primary tumor * Eligible for first-line systemic therapy with Sunitinib-targeted therapy for oncology urology * Affiliation to a social security scheme * Effective contraception (as defined by the WHO) for at least 3 months at the inclusion visit, during treatment and for 1 month after the end of the research (negative pregnancy test) * Postmenopausal woman: confirmatory diagnosis (amenorrhea not clinically induced for more than 12 months at inclusion visit) * General condition WHO 0 to 2 * Life expectancy estimated at more than 6 months at baseline Exclusion Criteria: * Non-metastatic disease * Other cancer proven histologically, or in complete remission for less than 2 years * Contraindication to SUTENT 50 mg hard capsules: Hypersensitivity to the active substance or to any of the excipients * History of immunotherapy treatment for kidney cancer, previous treatment with targeted therapies for the same or previous cancer * Pregnant or lactating woman or wishing to breastfeed within 6 months after the last treatment or no known contraception, * Person deprived of liberty by an administrative or judicial decision or person placed under the protection of justice / sub-guardianship or curatorship * Patient currently involved in an interventional trial

Locations (1)

CHU de ROUEN

Rouen, France